Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Barbara Holzer, Broadcast Manager
w. (202) 588-7716
bholzer@citizen.org

Karilyn Gower, Press Officer
w. (202) 588-7779
kgower@citizen.org

Symone Sanders, Communications Officer, Global Trade Watch division
w. (202) 454-5108
ssanders@citizen.org

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog
Facebook/publiccitizen

Follow us on Twitter

 

May 22, 2013         

FDA Should Reject Dangerous Sleep Medicine, Public Citizen Tells Advisory Committee

Like other sleep medicines, suvorexant is potentially habit-forming and impairs driving, posing grave risks to patients and public health

WASHINGTON, D.C. –The U.S. Food and Drug Administration (FDA) should not approve the new sleep medicine suvorexant because the drug’s long-lasting risks – both to patients and the general public – outweigh any short-term benefits to sleep, Public Citizen said today in testimony to the FDA’s Peripheral and Central Nervous Systems Drugs Advisory Committee.

Millions of Americans live with some form of sleep disorder. Suvorexant was developed to help some of these people get to sleep a bit more quickly and stay asleep for a few minutes longer.

However, suvorexant continues to exert its sleep-inducing effects long after a person wakes up in the morning because it stays in the body longer (for up to 3 days) than all but one of the currently available sleep medicines. Consequently, in the pre-approval studies, subjects given suvorexant at night experienced next-day drowsiness that was shown to impair their alertness and ability to drive. Five subjects (almost 5%) on suvorexant even had to stop the supervised driving tests for fear of falling asleep at the wheel.

Zolpidem (Ambien), another widely-used sleeping aid, has been associated with an increased risk of car accidents in at least two large studies to date, prompting a recent FDA alert warning patients not to drive the day after taking the drug. Suvorexant stays in the body six times longer than zolpidem, with patients more often than not unaware of their diminished ability to drive and perform other mental tasks.

Studies have found that suvorexant can cause suicidal thoughts, elevated cholesterol, and hallucinations. Public Citizen also testified that subjects who stopped using the drug experienced even worse sleep disturbances than they did before being placed on the drug. Patients on suvorexant could therefore likely become dependent on the drug over time, making it difficult to discontinue therapy even if side effects became severe.

“Like its predecessors, suvorexant’s marginal benefit in extending overnight sleep time by a few minutes is achieved at the expense of prolonged, next-day drowsiness, with potentially fatal consequences, in addition to a litany of other serious side effects” said Dr. Sammy Almashat, researcher with Public Citizen’s Health Research Group. “This drug poses far too great a risk to both patients and the general public to be on the market.”

To read today’s testimony, visit http://www.citizen.org/hrg2129

Copyright © 2014 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.


Public Citizen, Inc. and Public Citizen Foundation

 

Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.

 

To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.